These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18349472)

  • 1. Nephrogenic systemic fibrosis in stage 4 kidney disease, what is the alternative?
    Stassen PM
    Neth J Med; 2008 Mar; 66(3):132; author reply 133. PubMed ID: 18349472
    [No Abstract]   [Full Text] [Related]  

  • 2. Gadolinium use in patients with kidney disease: a cause for concern.
    Perazella MA; Rodby RA
    Semin Dial; 2007; 20(3):179-85. PubMed ID: 17555477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrogenic systemic fibrosis: experimental studies confound prevailing theory of free gadolinium as a causative factor.
    Jakobsen J
    Acta Radiol; 2008 Jul; 49(6):616-7. PubMed ID: 18568551
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to editorial: animal models for nephrogenic systemic fibrosis.
    Sieber MA; Lengsfeld P; Pietsch H
    Acta Radiol; 2008 Oct; 49(8):963-4. PubMed ID: 18798020
    [No Abstract]   [Full Text] [Related]  

  • 5. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital.
    Marckmann P
    Eur J Radiol; 2008 May; 66(2):187-90. PubMed ID: 18328659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nephrogenic systemic fibrosis: another problem for patients with chronic renal failure].
    Michelet PR; Chopard CS; Martin PY; Vallée JP
    Rev Med Suisse; 2008 Mar; 4(147):576-8, 580. PubMed ID: 18402015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?
    Thomsen HS; Marckmann P; Logager VB
    Acta Radiol; 2007 Jul; 48(6):593-6. PubMed ID: 17611863
    [No Abstract]   [Full Text] [Related]  

  • 8. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of gadolinium in triggering nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy.
    Solomon GJ; Rosen PP; Wu E
    Arch Pathol Lab Med; 2007 Oct; 131(10):1515-6. PubMed ID: 17922586
    [No Abstract]   [Full Text] [Related]  

  • 10. Validity of the animal models for nephrogenic systemic fibrosis.
    Morcos SK
    Invest Radiol; 2008 May; 43(5):338; author reply 338. PubMed ID: 18424956
    [No Abstract]   [Full Text] [Related]  

  • 11. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
    Singh M; Davenport A; Clatworthy I; Lewin J; Deroide F; Hubbard V; Rustin MH
    Br J Dermatol; 2008 Jun; 158(6):1358-62. PubMed ID: 18363754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrogenic systemic fibrosis: epidemiology update.
    Marckmann P
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):315-9. PubMed ID: 18408485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis.
    High WA; Ayers RA; Cowper SE
    J Am Acad Dermatol; 2007 Apr; 56(4):710-2. PubMed ID: 17289213
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update.
    Kanal E; Broome DR; Martin DR; Thomsen HS
    Radiology; 2008 Jan; 246(1):11-4. PubMed ID: 17855656
    [No Abstract]   [Full Text] [Related]  

  • 17. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors.
    Khurana A; Greene JF; High WA
    J Am Acad Dermatol; 2008 Aug; 59(2):218-24. PubMed ID: 18538448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide.
    Thomsen HS
    Eur Radiol; 2006 Dec; 16(12):2619-21. PubMed ID: 17061066
    [No Abstract]   [Full Text] [Related]  

  • 19. [Gadolinium: a true problem for the nephrologists?].
    Balducci A; Tamburrini O
    G Ital Nefrol; 2008; 25(1):3-4. PubMed ID: 18264906
    [No Abstract]   [Full Text] [Related]  

  • 20. Nephrogenic systemic fibrosis: recommendations for gadolinium-based contrast use in patients with kidney disease.
    Perazella MA; Reilly RF
    Semin Dial; 2008; 21(2):171-3. PubMed ID: 18226005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.